Myers Industries' beats Q4 expectations, approves $10M share buyback
Myers Industries (NYSE:MYE) shares surge 27% with Q4 results beating expectations, a $10M buyback plan, and revenue up 6.7%.
Why a Big Pharma player is shutting down a Bay Area site, consolidating at another
At one point, BMS said the facility would house 400 people. That was before Chairman and CEO Chris Boerner replaced Giovanni ...
Barchart on MSN2h
Is Bristol-Myers Stock Outperforming the Dow?
Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, and markets ...
BioSpace4h
Hiring Outlook: Job Market Yet to Heat Up, But Layoffs Cool Off
While hiring activity has not yet picked up, it should do so soon, according to BioSpace Recruitment Manager Greg Clouse.
Novartis not panicking over potential US pharmaceutical tariffs, chairman says
Novartis is not panicking about higher tariffs on pharmaceutical imports that U.S. President Donald Trump could impose, the ...
Investing Snacks15h
Bristol Myers Slashes 280 More Jobs in Cost-Cutting Push
Bristol Myers Squibb is axing another 280 jobs as part of its $1.5 billion cost-cutting plan. The company is laying off 223 ...
Peninsula medical device company to lop off $400 million in debt in bankruptcy plan
A Peninsula company that makes medical devices for body sculpting, tattoo removal, acne and more hopes to go private and ...
Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal
MyoKardia, a Bristol Myers unit, is terminating its agreement with Fulcrum Therapeutics, ending a cardiomyopathy research deal set to expire in June 2025.